JP2017525337A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525337A5
JP2017525337A5 JP2016573588A JP2016573588A JP2017525337A5 JP 2017525337 A5 JP2017525337 A5 JP 2017525337A5 JP 2016573588 A JP2016573588 A JP 2016573588A JP 2016573588 A JP2016573588 A JP 2016573588A JP 2017525337 A5 JP2017525337 A5 JP 2017525337A5
Authority
JP
Japan
Prior art keywords
cancer
bap1
biomarker
expression
ezh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525337A (ja
JP6684230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036677 external-priority patent/WO2015196064A1/en
Publication of JP2017525337A publication Critical patent/JP2017525337A/ja
Publication of JP2017525337A5 publication Critical patent/JP2017525337A5/ja
Application granted granted Critical
Publication of JP6684230B2 publication Critical patent/JP6684230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573588A 2014-06-19 2015-06-19 Ｅｚｈ２阻害剤への応答についてのバイオマーカー Expired - Fee Related JP6684230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19
US62/014,594 2014-06-19
PCT/US2015/036677 WO2015196064A1 (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Publications (3)

Publication Number Publication Date
JP2017525337A JP2017525337A (ja) 2017-09-07
JP2017525337A5 true JP2017525337A5 (OSRAM) 2018-07-26
JP6684230B2 JP6684230B2 (ja) 2020-04-22

Family

ID=54936135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573588A Expired - Fee Related JP6684230B2 (ja) 2014-06-19 2015-06-19 Ｅｚｈ２阻害剤への応答についてのバイオマーカー

Country Status (15)

Country Link
US (1) US20170138946A1 (OSRAM)
EP (1) EP3158086B1 (OSRAM)
JP (1) JP6684230B2 (OSRAM)
KR (1) KR20170020463A (OSRAM)
CN (1) CN106795561B (OSRAM)
AU (1) AU2015276899B2 (OSRAM)
BR (1) BR112016029911A2 (OSRAM)
CA (1) CA2952285A1 (OSRAM)
EA (1) EA036889B1 (OSRAM)
ES (1) ES2870096T3 (OSRAM)
IL (1) IL249443B (OSRAM)
MX (1) MX384423B (OSRAM)
SG (2) SG11201610610YA (OSRAM)
WO (1) WO2015196064A1 (OSRAM)
ZA (1) ZA201608555B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
JP7336193B2 (ja) * 2016-02-16 2023-08-31 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 原発性胃腺癌の体細胞プロモーター特性を明らかにするエピゲノムプロファイリング
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN118161615B (zh) * 2024-03-19 2025-08-12 山东大学齐鲁医院 Phf20抑制剂在制备抗皮肤癌药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1992010588A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2001055454A1 (en) 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
WO2002086168A1 (en) 2001-04-19 2002-10-31 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
EP1425695A2 (en) 2001-08-13 2004-06-09 Beyong Genomics, Inc. Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
WO2003091735A1 (en) 2002-04-23 2003-11-06 Millipore Corporation Sample preparation of biological fluids for proteomic applications
WO2007001986A2 (en) 2005-06-20 2007-01-04 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2012364924A1 (en) * 2011-02-16 2013-09-12 Medical University Of Graz BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
BR112014007603A2 (pt) * 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법

Similar Documents

Publication Publication Date Title
Reece et al. The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer
Yang et al. Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4
Luo et al. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression
Ding et al. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma
Chen et al. Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation, migration, and invasion in malignant glioma cells
Tang et al. LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer
Zhang et al. Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma
Li et al. Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma
Xie et al. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population
WO2012153187A4 (en) Markers for cancer prognosis and therapy and methods of use
KR102585110B1 (ko) 암 예후의 판정
Wu et al. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation
Seisen et al. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer
Gharib et al. Investigating the diagnostic performance of HOTTIP, PVT1, and UCA1 long noncoding RNAs as a predictive panel for the screening of colorectal cancer patients with lymph node metastasis
Li et al. Plasma miRNA-506 as a prognostic biomarker for esophageal squamous cell carcinoma
Pavlidou et al. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR
Jing et al. Prognostic and diagnostic significance of SDPR-Cavin-2 in hepatocellular carcinoma
Sudoyo et al. Increased CD8 tumor infiltrating lymphocytes in colorectal cancer microenvironment supports an adaptive immune resistance mechanism of PD-L1 expression
Song et al. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
Yang et al. LncRNA SAMMSON negatively regulates miR-9-3p in hepatocellular carcinoma cells and has prognostic values
Zhang et al. MAEL contributes to gastric cancer progression by promoting ILKAP degradation
Jing et al. Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE
Cui et al. Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab
Yang et al. Identification of a functional polymorphism within the 3′-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma
Chi et al. Clinical significance and prognostic value of TRIM24 expression in esophageal squamous cell carcinoma